Cerdulatinib

Global Vitiligo Market Report (2022 to 2027) - Featuring Incyte, Bristol-Myers Squibb and Clinuvel Pharmaceuticals Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022

Vitiligo Industry Growth Rate Affected by COVID-19 Pandemic:

Key Points: 
  • Vitiligo Industry Growth Rate Affected by COVID-19 Pandemic:
    In 2020, the vitiligo industry growth rate was affected by the COVID-19 pandemic.
  • According to the publisher, Global Vitiligo Market Size has reached US$ 3.5 Billion in 2021 post gradual recovery from the pandemic.
  • The report covers countries like the United States, India, China, Japan, Germany, United Kingdom, Italy, and France constituting the vitiligo market.
  • Globally, the United States market contributes for the largest market share for Vitiligo Market and dominates the overall market.

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Retrieved on: 
Wednesday, April 28, 2021

b"SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ --Rigel Pharmaceuticals,Inc.

Key Points: 
  • b"SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ --Rigel Pharmaceuticals,Inc.
  • (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021.
  • Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms.
  • The company's first FDA approved product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Global Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight Report 2020 Featuring Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM, TopiVert, Takeda Oncology & Asana BioSciences - ResearchAndMarkets.com

Retrieved on: 
Friday, February 5, 2021

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Retrieved on: 
Wednesday, February 3, 2021

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

Retrieved on: 
Monday, December 23, 2019

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2019 /PRNewswire/ --Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 23, 2019 /PRNewswire/ --Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.
  • The event is scheduled to take place on Tuesday, January 14, at 7 a.m. PT (10 a.m.
  • Portola will provide updates on Andexxa and Ondexxya and its investigational hematologic compound, the oralSYK/JAK inhibitor cerdulatinib.
  • To access the live investor webcast on Tuesday, January 14, at 7 a.m. PT (10 a.m.

Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

Retrieved on: 
Monday, December 9, 2019

The data will be presented today during a poster session at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando (December 7-10).

Key Points: 
  • The data will be presented today during a poster session at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando (December 7-10).
  • To date, 16 of the 42 patients (38%) in the cerdulatinib-only cohort have been on study drug for at least 10 months.
  • Among the 21 patients evaluated for efficacy in the cerdulatinib and rituximab combination cohort, the ORR was 76%; 5 patients (24%) achieved a CR, 11 patients (52%) achieved a PR and 5 patients (24%) achieved SD.
  • Cerdulatinib was generally well-tolerated and the safety profile appeared similar in both the cerdulatinib-only and rituximab combination cohorts.

Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

Retrieved on: 
Tuesday, December 3, 2019

BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.

Key Points: 
  • BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.
  • Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis.
  • With vitiligo affecting an estimated 65-95 million people worldwide, including approximately 2.4 million people in the U.S., I am excited to announce that the first vitiligo patient has been dosed with topical cerdulatinib in this Phase 2a clinical trial, said Todd Zavodnick, Chief Executive Officer of Dermavant.
  • Vitiligo is a chronic skin disease characterized by smooth, white patches of skin due to the loss of natural skin color.

Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019

"We are pleased to present data on two Portola medicines cerdulatinib and Andexxa at the ASH Annual Meeting," said Jeff Myers, M.D., Portola's interim chief medical officer.

Key Points: 
  • "We are pleased to present data on two Portola medicines cerdulatinib and Andexxa at the ASH Annual Meeting," said Jeff Myers, M.D., Portola's interim chief medical officer.
  • The U.S. Food and Drug Administration granted cerdulatinib Orphan Drug Designation for the treatment of PTCL in September 2018.
  • Treatment with Andexxa has been associated with serious and lifethreatening adverse events, including:
    Monitor for thromboembolic events and initiate anticoagulation when medically appropriate.
  • Continued approval for this indication may be contingent upon the results of studies to demonstrate an improvement in hemostasis in patients.

The global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period

Retrieved on: 
Tuesday, August 13, 2019

Global Janus Kinase (JAK) Inhibitors Market: About this market

Key Points: 
  • Global Janus Kinase (JAK) Inhibitors Market: About this market
    Global janus kinase (JAK) inhibitors are drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2.
  • Read the full report: https://www.reportlinker.com/p05804140/?utm_source=PRN Global Janus Kinase (JAK) Inhibitors Market: Overview
    The global JAK inhibitors market is expected to benefit significantly from the rising use of JAK inhibitors to treat various chronic diseases.
  • Such factors will lead to the expansion of the global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period.
  • With the presence of a few major players, the global janus kinase (JAK) inhibitors market is concentrated.

Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 22, 2019

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Janus Kinase (JAK) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Janus Kinase (JAK) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine